Renal Denervation Market (2026-2036)
The global renal denervation market was valued at USD 1.44 billion in 2026. This market is expected to reach USD 8.64 billion by 2036, growing at a CAGR of 19.6% during the forecast period 2026–2036.
- Published
- Jun 2026
- Pages
- 293
- Format
- PDF + Excel
- Report ID
- MRHC - 1042032
- Base year
- 2025
- 2026 · ESTIMATED
- $1.44B
- 2036
- $8.64B
- CAGR 2026–2036
- 19.6%
2025 baseline · 2026–2036 forecast at 19.6% CAGR · hover a bar for the value
Key highlights
The global renal denervation market is projected to reach USD 8.64 billion by 2036.
The market is expected to grow at a CAGR of 19.6% during the forecast period 2026–2036.
The global market is estimated at USD 1.44 billion in 2026.
FDA approvals of Medtronic’s Symplicity Spyral and ReCor Medical’s Paradise systems are primary catalysts.
Ultrasound-based renal denervation is the fastest-growing technology segment.
A sustained 5 mmHg reduction in systolic blood pressure is associated with an approximately 10–15% reduction in major cardiovascular events.
Renal denervation procedure volumes are expected to grow at a strong double-digit rate through 2030, supported by expanding reimbursement, favorable clinical evidence, and increasing physician adoption.
Resistant hypertension remains the largest indication for renal denervation therapy.
North America accounts for approximately 45% of the global market share in 2026.
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2036 |
| Market Size (2026) | USD 1.44 billion |
| Market Size (2036) | USD 8.64 billion |
| CAGR (2026–2036) | 19.6% |
| Format | PDF, Excel & Cloud Portal · 293 pages |
| Segments Covered | By Product: Catheters, Generators, Accessories · By Technology: Radiofrequency, Ultrasound, Micro-infusion · By Indication: Resistant Hypertension, Uncontrolled Hypertension, CKD · By End User |
| Key Companies | Medtronic plc, ReCor Medical, Inc., Boston Scientific Corporation, Otsuka Medical Devices, Terumo Corporation, MicroPort Scientific Corporation |
Report infographic
Market dynamics
6 factors across 5 forcesThe primary driver for the renal
denervation market is the recent regulatory clearance and commercial launch of clinically validated systems. FDA approvals have provided the necessary confidence for physicians and payers to adopt the technology. Furthermore, the expansion of reimbursement coverage, including the establishment of specific CPT codes in the U.S., is facilitating patient access. The rising global prevalence of resistant hypertension and the growing patient preference for device-based therapies to reduce the burden of daily medication are also significant drivers.
Table of contents
12 chapters · 102 sections · 293 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Technology | Radiofrequency | Ultrasound-Based |
| By Indication | Resistant Hypertension | Uncontrolled Hypertension |
By Technology
- Radiofrequency Segment to Hold Largest Share
- The Radiofrequency segment is expected to hold the largest share of the market.
- This dominance is driven by the extensive clinical history and the massive commercial footprint of Medtronic’s Symplicity platform, which has been the primary focus of early market development.
- The Ultrasound-Based segment is projected to witness the fastest growth during the forecast period.
- The superior depth of denervation and the strong clinical outcomes from the Paradise platform are driving its rapid adoption among interventionalists.
By Indication
- Resistant Hypertension to Lead
- The Resistant Hypertension segment is expected to hold the largest share of the market.
- This is the primary indication for which current systems are approved and reimbursed, representing the most urgent clinical need.
- The Uncontrolled Hypertension segment is projected to witness the fastest growth as indications expand to include patients who may be able to tolerate medication but prefer a device-based solution to reduce their daily pill burden.
Geographic analysis
North America
Largest shareNorth America is expected to hold the largest share of the global renal denervation market in 2026, accounting for approximately 45% of the total revenue. This is due to the rapid commercial launch of FDA-approved systems, a favorable reimbursement landscape with specific CPT codes, and a high concentration of specialized cardiac centers. Key companies operating in the North American market include Medtronic and ReCor Medical.
Asia-Pacific
Fastest growthAsia-Pacific is projected to witness the fastest growth during the forecast period. The region faces a massive hypertension burden, particularly in Japan and China. The recent introduction of ultrasound-based RDN in Japan and the increasing investment in cardiovascular research in China are the primary growth drivers. Key companies operating in the Asia-Pacific market include Otsuka Medical Devices and major global vendors.
Competitive landscape
- Medtronic plc
- ReCor Medical, Inc.
- Boston Scientific Corporation
- Otsuka Medical Devices, Terumo Corporation
- MicroPort Scientific Corporation
Frequently asked questions
The market is projected to reach USD 8.64 billion by 2036, growing at a CAGR of 19.6% from 2026 to 2036.
Cite this report
Meticulous Research. (2026). Renal Denervation Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MRHC - 1042032). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/renal-denervation-market-6716